[{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HLX07","moa":"EGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Sanyou Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Antibody drug conjugate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Henlius Biotech \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"HLX71","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0.56999999999999995,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.56999999999999995,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ ACCORD HEALTHCARE","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ ACCORD HEALTHCARE"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Denosumab","moa":"TNFSF11","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rituximab","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Oncology","graph2":"IND Enabling","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"HLX301","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-L1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Serplulimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Pertuzumab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Palleon Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Bifunctional HER2-Sialidase","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Shanghai Henlius Biotech","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Shanghai Henlius Biotech \/ Shanghai Henlius Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Henlius Biotech \/ Shanghai Henlius Biotech"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Carboplatin","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HLX22","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HLX07","moa":"EGFR","graph1":"Oncology","graph2":"Phase II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Fosun Pharma"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Kalbe Genexine Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0.67000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.67000000000000004,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Kalbe Genexine Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Kalbe Genexine Biologics"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluorouracil","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Serplulimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Organon","highestDevelopmentStatusID":"10","companyTruncated":"Shanghai Henlius Biotech \/ Organon"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Pertuzumab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Shanghai Henlius Biotech \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Shanghai Henlius Biotech \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Shanghai Henlius Biotech
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
